WO2006078780A3 - Rdc1 antibodies for the diagnosis of nsclc - Google Patents

Rdc1 antibodies for the diagnosis of nsclc Download PDF

Info

Publication number
WO2006078780A3
WO2006078780A3 PCT/US2006/001841 US2006001841W WO2006078780A3 WO 2006078780 A3 WO2006078780 A3 WO 2006078780A3 US 2006001841 W US2006001841 W US 2006001841W WO 2006078780 A3 WO2006078780 A3 WO 2006078780A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsclc
rdc1
antibodies
diagnosis
cancers
Prior art date
Application number
PCT/US2006/001841
Other languages
French (fr)
Other versions
WO2006078780A2 (en
Inventor
Beverly Teicher
Bruce Roberts
Srinivas Shankara
Original Assignee
Genzyme Corp
Beverly Teicher
Bruce Roberts
Srinivas Shankara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Beverly Teicher, Bruce Roberts, Srinivas Shankara filed Critical Genzyme Corp
Publication of WO2006078780A2 publication Critical patent/WO2006078780A2/en
Publication of WO2006078780A3 publication Critical patent/WO2006078780A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Abstract

The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of cancers, e.g., NSCLC, of epithelial origin, e.g., ovarian, lung and prostate cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of antigens associated with these cancers and malignancies.
PCT/US2006/001841 2005-01-19 2006-01-19 Rdc1 antibodies for the diagnosis of nsclc WO2006078780A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64534805P 2005-01-19 2005-01-19
US60/645,348 2005-01-19

Publications (2)

Publication Number Publication Date
WO2006078780A2 WO2006078780A2 (en) 2006-07-27
WO2006078780A3 true WO2006078780A3 (en) 2007-07-26

Family

ID=36692851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001841 WO2006078780A2 (en) 2005-01-19 2006-01-19 Rdc1 antibodies for the diagnosis of nsclc

Country Status (1)

Country Link
WO (1) WO2006078780A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088895B2 (en) * 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2010141986A1 (en) * 2009-06-09 2010-12-16 Mabdesign Pty Ltd Novel antibodies and uses therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers
US20050074826A1 (en) * 2001-11-30 2005-04-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20050074826A1 (en) * 2001-11-30 2005-04-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
WO2004001004A2 (en) * 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Membrane associated tumor endothelium markers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BALABANIAN K. ET AL.: "The Chemokine SDF-1/CXCL12 Binds to and Signals through the Orphan Receptor RDC1 in T Lymphocytes", J. OF BIOLOGICAL CHEMISTRY, vol. 280, 2005, pages 35760 - 35766, XP003015681 *
INFANTINO S. ET AL.: "Expression and Regulation of the Orphan Receptor RDC1 and Its Putative Ligand in Human Dendritic and B Cells", JOURNAL OF IMMUNOLOGY, vol. 176, 2006, pages 2197 - 2207, XP003015680 *
SREEDHARAN S.P. ET AL.: "CLONING AND EXPRESSION OF THE HUMAN VASOACTIVE INTESTINAL PEPTIDE RECEPTOR", PNAS, vol. 88, no. 11, 1991, pages 4986 - 4990, XP002146889 *

Also Published As

Publication number Publication date
WO2006078780A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
WO2006078911A3 (en) Gitr antibodies for the diagnosis of nsclc
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
CA2602088C (en) Biomarkers for ovarian cancer and endometrial cancer
WO2008097908A3 (en) Methods of diagnosing and prognosing lung cancer
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
JP2014074724A5 (en)
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
MX355020B (en) Lung cancer biomarkers and uses thereof.
CA2844033C (en) Method for detecting pancreatic cancer
MX367366B (en) Compositions and methods for diagnosing thyroid tumors.
TW200801202A (en) Alpha-enolase specific antibody and method of use
BR112013000869A2 (en) method for diagnosing prostate cancer (pca) with a desired sensitivity in a subject; method for monitoring the progression of prostate cancer (pca) in a subject; method for assessing whether a subject has to undergo a prostate biopsy; kit comprising a first component and optionally a second component and use of a kit
MX2010009766A (en) Protease assay.
IN2013CN01129A (en)
GB2478441A (en) Lung cancer biomarkers and uses thereof
MX2012005995A (en) Novel genomic biomarkers for irritable bowel syndrome diagnosis.
WO2007048978A3 (en) Method for detecting cancer
WO2009055820A3 (en) Salivary protein biomarkers for human oral cancer
WO2006102526A3 (en) Identification of biomarkers by serum protein profiling
WO2009007846A3 (en) Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
WO2013036754A3 (en) Methods and compositions for diagnosis of ovarian cancer
MX2009010751A (en) Compositions and methods of detection.
WO2011087709A3 (en) Eml4-alk translocations in lung cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06718849

Country of ref document: EP

Kind code of ref document: A2